Added to YB: 2025-10-27
Pitch date: 2025-09-30
VRTX [neutral]
Vertex Pharmaceuticals Incorporated
+14.84%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$393.62
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
N/A
Show full summary:
Alger Weatherbie Specialized Growth Fund Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): Tax compliance software for large enterprises (250+ employees) via cloud/on-premises ERP integration. Strong Q2 results but lowered FY revenue guidance due to uncertain demand as customers delay ERP/software implementations, causing share decline despite solid execution.
Read full article (1 min)